View the latest news and SEC filings
Scroll to
LONDON and RALEIGH, N.C., May 21, 2025 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that senior management will participate in fireside chats at the following conferences in June 2025: Jefferies Global Healthcare Conference Date: Wednesday, June
Analyses support Ohtuvayre® (ensifentrine) as a first-in-class selective dual inhibitor of PDE3 and PDE4 for a broad COPD population LONDON and RALEIGH, N.C., May 06, 2025 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona” or the “Company”), a biopharmaceutical company focused on
Total net revenue of $76.3 million from Q1 2025 driven by Ohtuvayre ® net sales of $71.3 million (+95% vs Q4 2024) ~25,000 prescriptions filled in Q1 2025 Q1 2025 revenue exceeds operating expenses excluding non-cash charges Conference call today at 9:00 a.m. EDT / 2:00 p.m.
LONDON and RALEIGH, N.C., April 15, 2025 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that it will report its financial results for the first quarter ended March 31, 2025 on Tuesday, April 29, 2025 and host an investment community conference call
| Date | Form | Filing Group | ||
|---|---|---|---|---|
|
April 30, 2024 |
Statement of changes in beneficial ownership of securities |
4 |
3,4,5 |
|
|
April 30, 2024 |
Statement of changes in beneficial ownership of securities |
4 |
3,4,5 |
|
|
April 30, 2024 |
Report of unscheduled material events or corporate event |
8-K |
Current Reports |
|
|
April 2, 2024 |
Statement of changes in beneficial ownership of securities |
4 |
3,4,5 |
|
|
March 20, 2024 |
An annual report to security holders |
ARS |
Annual Filings |
|
|
March 20, 2024 |
Official notification to shareholders of matters to be brought to a vote (“Proxy”) |
DEF 14A |
Proxy Filings |
|
|
March 12, 2024 |
Filed by “insiders” prior intended sale of restricted stock. Non-EDGAR filing |
144 |
Other |
|
|
March 8, 2024 |
A preliminary proxy statement providing notification matters to be brought to a vote |
PRE 14A |
Proxy Filings |
|
|
March 7, 2024 |
Initial filing by director officer or owner of more than ten percent |
3 |
3,4,5 |
Verona Pharma (Nasdaq:VRNA) is focused on delivering our strategy and creating value for shareholders.
